Dr. Morris, while I have you, you seem to feel that bamlanivimab was totally useless. Maybe you could comment on the Chen et al. study in The New England Journal of Medicine. Their numbers were such that when it's used early, I think it decreased emergency room and hospitalization rates from 6.3% to 1.6%, and, in those who are either obese or over 65, from 14% to 4.6%.
Then, there's the BLAZE-2 trial. Dr. Silverman at Western, the head of infectious disease, said about bamlanivimab that apparently there have been six different groups of infectious disease people in Ontario trying to use it and, according to Dr. Silverman, there are no trials suggesting that it doesn't work whereas there are several suggesting that early on in the disease it is effective, so....